TAG-72 Antibody (Minretumomab (CC49)) - Chimeric - Azide and BSA Free
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-09038
Recombinant Monoclonal Antibody
Key Product Details
Species Reactivity
Human
Applications
Flow Cytometry, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Radioimmunoassay, Western Blot
Label
Unconjugated
Antibody Source
Recombinant Monoclonal Rabbit IgG Kappa Clone # Minretumomab (CC49)
Format
Azide and BSA Free
Concentration
1 mg/ml
Product Specifications
Immunogen
This antibody was raised by immunising BALB/c mice with TAG-72 purified from LS-174T human carcinoma xenograft.
Specificity
This antibody is specific for the disaccharide sialyl Tn epitope of human TAG-72. TAG-72 is expressed on a wide range of human carcinomas, including colorectal cancers.
Clonality
Monoclonal
Host
Rabbit
Isotype
IgG Kappa
Description
Novus Biologicals Rabbit TAG-72 Antibody (Minretumomab (CC49)) - Chimeric - Azide and BSA Free (NBP3-09038) is a recombinant monoclonal antibody validated for use in IHC, WB, Flow and ICC/IF. All Novus Biologicals antibodies are covered by our 100% guarantee.
Scientific Data Images for TAG-72 Antibody (Minretumomab (CC49)) - Chimeric - Azide and BSA Free
Immunocytochemistry/ Immunofluorescence: TAG-72 Antibody (Minretumomab (CC49)) - Chimeric - Azide and BSA Free [NBP3-09038]
Immunocytochemistry/Immunofluorescence: TAG-72 Antibody (Minretumomab (CC49)) - Chimeric [NBP3-09038] - Immunofluorescence analysis of paraformaldehyde fixed Jurkat cells immobilized on Shi-fix(TM) cover-slips and stained with the chimeric rabbit IgG version of Minretumomab (CC49) (NBP3-09038) at 10 ug/ml followed by Alexa Fluor(R) 488 secondary antibody (2 ug/ml), showing strong membrane staining. The nuclear stain is DAPI (blue). Panels show from left-right, top-bottom NBP3-09038, DAPI, merged channels and an isotype control. The isotype control was stained with anti-Fluorescein antibody followed by Alexa Fluor(R) 488 secondary antibody.Flow Cytometry: TAG-72 Antibody (Minretumomab (CC49)) - Chimeric - Azide and BSA Free [NBP3-09038]
Flow Cytometry: TAG-72 Antibody (Minretumomab (CC49)) - Chimeric [NBP3-09038] - Jurkat cells were stained with anti-Fluorescein IgG antibody (4-4-20; isotype control, black line) or the rabbit IgG1 version of Minretumomab (CC49 ) (NBP3-09038, blue line) at a dilution of 1:100 for 1h at RT. After washing, bound antibody was detected using a goat anti-mouse IgG AlexaFluor(R) 488 antibody at a dilution of 1:1000 and cells analyzed using a FACSCanto flow-cytometer.Applications for TAG-72 Antibody (Minretumomab (CC49)) - Chimeric - Azide and BSA Free
Application
Recommended Usage
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Immunocytochemistry/ Immunofluorescence
Optimal dilutions of this antibody should be experimentally determined.
Immunohistochemistry
Optimal dilutions of this antibody should be experimentally determined.
Radioimmunoassay
Optimal dilutions of this antibody should be experimentally determined.
Western Blot
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques.
The reactivity of this antibody with colon cancer extract and purified TAG-72 has been confirmed in solid-phase radioimmunoassays, and its reactivity with formalin-fixed carcinoma tissue sections confirmed in immunoperoxidase studies (Muraro et al, 1988). In flow cytometric analysis of freshly-isolated human carcinoma cells, this antibody reacts more strongly than the anti-TAG-72 MAb B72.3 (Muraro et al, 1988). Equally, flow cytometric analyses using this antibody have revealed that TAG-72 is expressed by certain haematopoietic cell lines (Nicolet et al, 1997). In western blot analysis, this antibody reacts with TAG-72 (Muraro et al, 1988). A humanised version of this antibody has been shown to be safe and sensitive in detecting recurrent colorectal carcinomas in radioimmunoguided surgery (Agnese et al, 2004), while radioimmunotherapy with an iodine-131-conjugated antibody has been shown to have a significant therapeutic effect on metastatic colon carcinoma in Phase I trials (Divgi et al, 1995).
The reactivity of this antibody with colon cancer extract and purified TAG-72 has been confirmed in solid-phase radioimmunoassays, and its reactivity with formalin-fixed carcinoma tissue sections confirmed in immunoperoxidase studies (Muraro et al, 1988). In flow cytometric analysis of freshly-isolated human carcinoma cells, this antibody reacts more strongly than the anti-TAG-72 MAb B72.3 (Muraro et al, 1988). Equally, flow cytometric analyses using this antibody have revealed that TAG-72 is expressed by certain haematopoietic cell lines (Nicolet et al, 1997). In western blot analysis, this antibody reacts with TAG-72 (Muraro et al, 1988). A humanised version of this antibody has been shown to be safe and sensitive in detecting recurrent colorectal carcinomas in radioimmunoguided surgery (Agnese et al, 2004), while radioimmunotherapy with an iodine-131-conjugated antibody has been shown to have a significant therapeutic effect on metastatic colon carcinoma in Phase I trials (Divgi et al, 1995).
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
PBS
Format
Azide and BSA Free
Preservative
0.02% Proclin 300
Concentration
1 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: TAG-72
Alternate Names
CA 72-4, Protein TAG-72, tag 72, tag-72 Protein TAG-72
Additional TAG-72 Products
Product Documents for TAG-72 Antibody (Minretumomab (CC49)) - Chimeric - Azide and BSA Free
Product Specific Notices for TAG-72 Antibody (Minretumomab (CC49)) - Chimeric - Azide and BSA Free
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...